Johnson & Johnson (JNJ)vsQiagen NV (QGEN)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
QGEN
Qiagen NV
$50.33
+0.32%
HEALTHCARE · Cap: $9.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 4629% more annual revenue ($99.33B vs $2.10B). QGEN leads profitability with a 19.5% profit margin vs 16.2%. QGEN appears more attractively valued with a PEG of 1.17. QGEN earns a higher WallStSmart Score of 60/100 (C+).
JNJ
Buy57
out of 100
Grade: C
QGEN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Margin of Safety
-27.3%
Fair Value
$40.12
Current Price
$50.33
$10.21 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Strong operational efficiency at 26.3%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.3% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : QGEN
The strongest argument for QGEN centers on Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 26.3%. PEG of 1.17 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while QGEN is a value play — different risk/reward profiles.
QGEN carries more volatility with a beta of 0.61 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
QGEN scores higher overall (60/100 vs 57/100), backed by strong 19.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?